Hilde Windels graduated in commercial engineering from the Katholieke Universiteit van Leuven (KU Leuven). She started her career in 1988 in the banking sector, where she was appointed a senior executive at the age of 30.
In 1998, Windels made the switch to the biotech sector, becoming the CFO of Devgen, a Belgium-based multinational agricultural biotech company specialized in crop protection. 10 years later, she moved on as the CEO of Devgen's spin-off pharma arm, BioDev. Windels served as an independent CFO for other biotech companies, including Pronota and TiGenix, when she joined Biocartis in 2011, a company established by Rudi Pauwels that specializes in molecular diagnostics. There, she started as CFO and transitioned into the role of co-CEO in 2015 and CEO ad interim in 2017.
Today, Windels has almost 20 years of experience in multiple domains, such as private fundraising, mergers and acquisitions, business and corporate strategy and public capital markets. Her impressive track record includes positions on the boards of Devgen, Biocartis, Ablynx, Erytech, MyCartis, MDx Health, Celyad, the Flanders Institute for Biotechnology (VIB), flanders.bio and Scale Health.
Currently, Windels is the CEO of new UGent and MyCartis spin-off Antelope Dx, which develops an innovative, easy-to-use home testing device that offers fast and accurate results. The first test to be marketed is a COVID-19/flu test.
Antelope Dx aims to provide high-quality health testing to every individual, anytime, anywhere.
As a dedicated health care innovator, Antelope DX believes that people should have immediate access to information about their own health. As a result, the company’s products generate actionable insights based on reliable analysis of self-collected samples.
In offering these solutions, Antelope Dx translates the complexity and performance of lab testing into an easy-to-use and affordable option that can be performed at home.